Tracers / [211At]At-astatobenzoate

[211At]At-astatobenzoate

Also written as [At-211]astatobenzoate
Radionuclide
At-211 t½ 431 min
Modality
Therapy
Production route
Stage
Syntheses indexed
3

What it is

Compound class
astatobenzoate/astatobenzamide (para-astatobenzoic acid derivative)
Target / mechanism
Clinical application
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
38283213
2024 RSC Med Chem
Manual synthesisHPLC74Para-Tri-n-Butylstannylbenzamidyl-dPEG4-Carboxylic Acid Methyl Ester, 936142567
2022 Int J Mol Sci
To a solution containing 100 μg 9 in 100 μL of a 0.05 N HCl MeOH/H2O and 200 μL of a [211At]NaAt solution, pH = 7, ~85 MBq (2.3 mCi), was added 20 μL of a 1 mg/mL aqueous solution of ChT. — a 74% radiochemical yield of [211At]13 by radio-HPLC analysis
70-75%trialkylstannyl precursor9234271
1994 Nucl Med Biol

Need this precursor?We can point you to suppliers for [211At]At-astatobenzoate, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 9 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36142567: 'Para-Tri-n-Butylstannylbenzamidyl-dPEG4-Carboxylic Acid Methyl Ester, 9'.